{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Sensory+Neuropathy&page=2", "query": { "condition": "Sensory Neuropathy", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Sensory+Neuropathy&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-10T17:53:03.428Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00600275", "title": "A Phase I/II Study of BGT226 in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumors", "Breast Cancer", "Cowden Syndrome" ], "interventions": [ { "name": "BGT226", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 57, "start_date": "2007-12", "completion_date": null, "has_results": false, "last_update_posted_date": "2020-12-17", "last_synced_at": "2026-06-10T17:53:03.428Z", "location_count": 4, "location_summary": "Boston, Massachusetts • Las Vegas, Nevada • San Antonio, Texas", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Las Vegas", "state": "Nevada" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00600275" }, { "nct_id": "NCT04798378", "title": "NuroSleeve Powered Brace & Stimulation System to Restore Arm Function", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Neurologic Diseases", "Hemiparesis", "Quadriplegia", "Muscular Dystrophies", "Arthrogryposis", "Spinal Cord Injuries", "Charcot-Marie-Tooth", "Stroke", "Weakness of Extremities as Sequela of Stroke", "Weakness Due to Upper Motor Neuron Dysfunction", "Amyotrophic Lateral Sclerosis", "Spinal Muscular Atrophy", "Arm Paralysis", "Cerebral Palsy" ], "interventions": [ { "name": "Neurosleeve", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Thomas Jefferson University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "4 Years", "maximum_age": null, "sex": "ALL", "summary": "4 Years and older" }, "enrollment_count": 20, "start_date": "2020-04-16", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2025-04-09", "last_synced_at": "2026-06-10T17:53:03.428Z", "location_count": 2, "location_summary": "Wilmington, Delaware • Philadelphia, Pennsylvania", "locations": [ { "city": "Wilmington", "state": "Delaware" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04798378" }, { "nct_id": "NCT00000842", "title": "A Phase II, Double-Blind Trial of Recombinant Human Nerve Growth Factor for Treatment of HIV-Associated Sensory Neuropathy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infections", "Peripheral Nervous System Disease" ], "interventions": [ { "name": "Nerve Growth Factor, Recombinant Human", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 270, "start_date": null, "completion_date": "1999-02", "has_results": false, "last_update_posted_date": "2021-11-04", "last_synced_at": "2026-06-10T17:53:03.428Z", "location_count": 14, "location_summary": "Los Angeles, California • San Mateo, California • Stanford, California + 10 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Mateo", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00000842" }, { "nct_id": "NCT03056755", "title": "Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Alpelisib", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Goserelin", "type": "DRUG" }, { "name": "Leuprolide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 383, "start_date": "2017-08-29", "completion_date": "2024-11-12", "has_results": true, "last_update_posted_date": "2026-01-13", "last_synced_at": "2026-06-10T17:53:03.428Z", "location_count": 25, "location_summary": "Gilbert, Arizona • Phoenix, Arizona • Anaheim, California + 20 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Anaheim", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Irvine", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03056755" }, { "nct_id": "NCT04278768", "title": "Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Acute Myelogenous Leukemia", "Myelodysplastic Syndrome" ], "interventions": [ { "name": "Emavusertib", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Curis, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 366, "start_date": "2020-07-06", "completion_date": "2026-04-01", "has_results": false, "last_update_posted_date": "2026-03-19", "last_synced_at": "2026-06-10T17:53:03.428Z", "location_count": 12, "location_summary": "Tampa, Florida • Atlanta, Georgia • Chicago, Illinois + 8 more", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04278768" }, { "nct_id": "NCT01633060", "title": "A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Breast Cancer" ], "interventions": [ { "name": "Fulvestrant", "type": "DRUG" }, { "name": "BKM120", "type": "DRUG" }, { "name": "BKM120 matching placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 432, "start_date": "2012-10-03", "completion_date": "2017-09-21", "has_results": true, "last_update_posted_date": "2019-01-30", "last_synced_at": "2026-06-10T17:53:03.428Z", "location_count": 37, "location_summary": "Mobile, Alabama • Chandler, Arizona • Fayetteville, Arkansas + 24 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01633060" }, { "nct_id": "NCT04572893", "title": "Exploratory Study of Danicamtiv in Patients With Primary Dilated Cardiomyopathy (DCM) Due to Genetic Variants or Other Causalities", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Primary Familial Dilated Cardiomyopathy" ], "interventions": [ { "name": "danicamtiv", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 41, "start_date": "2020-08-04", "completion_date": "2024-02-22", "has_results": true, "last_update_posted_date": "2025-05-21", "last_synced_at": "2026-06-10T17:53:03.428Z", "location_count": 12, "location_summary": "La Jolla, California • Washington D.C., District of Columbia • Tampa, Florida + 9 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Tampa", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04572893" }, { "nct_id": "NCT04218071", "title": "Actuate 1901: 9-ING-41 in Myelofibrosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Myelofibrosis" ], "interventions": [ { "name": "Ruxolitinib", "type": "DRUG" }, { "name": "9-ING-41", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Actuate Therapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2020-08-20", "completion_date": "2024-01-18", "has_results": false, "last_update_posted_date": "2024-02-07", "last_synced_at": "2026-06-10T17:53:03.428Z", "location_count": 9, "location_summary": "Los Angeles, California • Augusta, Georgia • Rochester, Minnesota + 5 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT04218071" }, { "nct_id": "NCT06993844", "title": "Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumors", "Advanced Breast Cancer" ], "interventions": [ { "name": "ETX-636 dose escalation", "type": "DRUG" }, { "name": "ETX-636 dose escalation in combination with fulvestrant", "type": "DRUG" }, { "name": "ETX-636 dose expansion in combination with fulvestrant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ensem Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 233, "start_date": "2025-06-10", "completion_date": "2027-12-30", "has_results": false, "last_update_posted_date": "2026-05-06", "last_synced_at": "2026-06-10T17:53:03.428Z", "location_count": 10, "location_summary": "Newport Beach, California • San Francisco, California • New Haven, Connecticut + 6 more", "locations": [ { "city": "Newport Beach", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06993844" }, { "nct_id": "NCT05011006", "title": "NT-3 Levels and Function in Individuals With CMT", "overall_status": "NOT_YET_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Charcot-Marie-Tooth Disease", "Peripheral Neuropathy", "Chronic Inflammatory Demyelinating Polyneuropathy" ], "interventions": [ { "name": "NT3 blood draw", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DIAGNOSTIC_TEST" ], "sponsor": "Zarife Sahenk", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "7 Years", "maximum_age": null, "sex": "ALL", "summary": "7 Years and older" }, "enrollment_count": 50, "start_date": "2027-11-13", "completion_date": "2030-06", "has_results": false, "last_update_posted_date": "2025-06-24", "last_synced_at": "2026-06-10T17:53:03.428Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT05011006" } ] }